Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.17)
# 1,050
Out of 4,829 analysts
110
Total ratings
35.58%
Success rate
3.68%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $65 | $1.48 | +4,291.89% | 1 | Mar 19, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.87 | +1,279.31% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.56 | +989.74% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.03 | +967.96% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $35.30 | +41.64% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.22 | +1,293.44% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.27 | +8,139.70% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $1.83 | +5,746.99% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.33 | +4,182.66% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.55 | +4,222.58% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $2.31 | +1,761.47% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.15 | +192.68% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.93 | +707.23% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.44 | +941.67% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $6.45 | +225.58% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $3.91 | +871.87% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.87 | +4,497.70% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.57 | +779.35% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $6.62 | +1,622.05% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $2.72 | +7,252.94% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $10.39 | +217.61% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $17.52 | +128.31% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $0.91 | +4,296.09% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.84 | +1,910.87% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $3.83 | +736.60% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $11.59 | +564.37% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.67 | +10,296.55% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.16 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $13.97 | +257.91% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $2.20 | +1,403.42% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.86 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $3.80 | +585.11% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $139.43 | -79.92% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.60 | +15,078.57% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $7.39 | +184.36% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Mar 19, 2025
Initiates: Buy
Price Target: $65
Current: $1.48
Upside: +4,291.89%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.87
Upside: +1,279.31%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.56
Upside: +989.74%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.03
Upside: +967.96%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $35.30
Upside: +41.64%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.22
Upside: +1,293.44%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.27
Upside: +8,139.70%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $1.83
Upside: +5,746.99%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.33
Upside: +4,182.66%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.55
Upside: +4,222.58%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $2.31
Upside: +1,761.47%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.15
Upside: +192.68%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.93
Upside: +707.23%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.44
Upside: +941.67%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $6.45
Upside: +225.58%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $3.91
Upside: +871.87%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.87
Upside: +4,497.70%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.57
Upside: +779.35%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $6.62
Upside: +1,622.05%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $2.72
Upside: +7,252.94%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $10.39
Upside: +217.61%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $17.52
Upside: +128.31%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $0.91
Upside: +4,296.09%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.84
Upside: +1,910.87%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $3.83
Upside: +736.60%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $11.59
Upside: +564.37%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.67
Upside: +10,296.55%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.16
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $13.97
Upside: +257.91%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $2.20
Upside: +1,403.42%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $9.86
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $3.80
Upside: +585.11%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $139.43
Upside: -79.92%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.60
Upside: +15,078.57%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $7.39
Upside: +184.36%